Table 2.

Grade 3 or higher toxicities, readmission rates and mortality during the neoadjuvant treatment of patients with pancreatic adenocarcinoma

Grade 3 or higher toxicities	Number of studies reporting the studied outcome	%	95% confidence interval
Overall	39	36%	27–45%
Hematologic	16	25%	14–38%
Anemia	33	4%	3–6%
Leukopenia	26	25%	18–32%
Lymphopenia	8	13%	4–24%
Neutropenia	38	23%	17–29%
Febrile neutropenia	17	3%	1–5%
Thrombocytopenia	41	7%	5–10%
Non hematologic	17	16%	7–27%
Nausea/vomiting	40	7%	4–10%
Diarrhea	38	4%	2–6%
Anorexia	19	3%	1–6%
Fatigue	26	4%	1–7%
Biliary obstruction/cholangitis	22	5%	3–7%
GI bleed, gastritis, or duodenitis,	14	3%	1–7%
Hospitalization rate	15	21%	14–27%
% of patients completing neoadjuvant therapy	42	90%	87%–93%
Mortality	48	0%	0–1%